⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12425843 | 1.00 | — | — | |
| SCHEMBL893651 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL27803981 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL8036195 | 0.98 | — | — | |
| SCHEMBL4999678 | 0.93 | — | — | |
| SCHEMBL25015337 | 0.91 | CYP1A2 (0.38) | — | |
| SCHEMBL16511457 | 0.91 | CYP1A2 (0.38) | — | |
| Formic Acid SCHEMBL31221547 | 0.88 | CPN1 (0.42) | — | |
| Formic Acid SCHEMBL28924639 | 0.88 | CPN1 (0.42) | — | |
| Formic Acid SCHEMBL29067106 | 0.88 | CPN1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068514-A1 | SUBSTITUTED HETEROCYCLIC CARBOXAMINDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2025-04-03 | — | — | WO | disclosed |
| US-11827920-B2 | Nanostructure, a biosensor including the nanostructure, and a screening method | POSTECH Research and Business Development Foundation (KR) | 2023-11-28 | — | — | US | disclosed |
| EP-3628044-B1 | PYRROLO[2,3-C]PYRIDINES AND RELATED ANALOGS AS LSD-1 INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023122298-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | Stablix, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230174486-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2023-06-08 | — | — | US | disclosed |
| WO-2023081840-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023078451-A1 | COMPOUND USED AS CDK7 KINASE INHIBITOR AND USE THEREOF | 浙江同源康医药股份有限公司 | 2023-05-11 | — | — | WO | disclosed |
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2021133750-A1 | SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-01 | — | — | WO | disclosed |
| US-20210087190-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20110086842-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-14 | — | — | US | disclosed |
| US-20100190764-A1 | Novel compounds | GLAXO GROUP LIMITED | 2010-07-29 | — | — | US | disclosed |
| CN-101723879-A | Method for synthesizing (R)-3-ethyl piperidine hydrochloride | UNIV EAST CHINA NORMAL | 2010-06-09 | — | — | CN | disclosed |
| EP-2178823-A1 | SPIRO CYCLOPENTANE COMPOUNDS USEFUL AS ANTAGONISTS OF THE H1-RECEPTOR | Glaxo Group Limited (GB) | 2010-04-28 | — | — | EP | disclosed |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
| WO-2009016084-A1 | SPIRO CYCLOPENTANE COMPOUNDS USEFUL AS ANTAGONISTS OF THE H1-RECEPTOR | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | WO | disclosed |
| EP-1771425-B1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2008-05-14 | — | — | EP | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |